Table 3. Adjusted associations between cinacalcet use and clinical outcomes, computed using marginal structural models, stratified by baseline iPTH categorya.
Baseline iPTH pg/ml | Adjusted RR | 95% CI | p-value |
---|---|---|---|
Death due to any causeb | |||
<300 | 1.07 | 0.77–1.48 | 0.682 |
300–<500 | 0.88 | 0.61–1.29 | 0.517 |
≥500 | 0.49 | 0.29–0.82 | 0.007 |
Death due to cardiovascular diseaseb | |||
<300 | 0.92 | 0.56–1.50 | 0.725 |
300–<500 | 0.87 | 0.45–1.70 | 0.691 |
≥500 | 0.69 | 0.37–1.32 | 0.264 |
Cardiovascular hospitalization or deathc | |||
<300 | 1.05 | 0.77–1.42 | 0.766 |
300–<500 | 0.71 | 0.47–1.05 | 0.087 |
≥500 | 0.67 | 0.43–1.06 | 0.087 |
RR: incidence rate ratio, 95% CI: 95% confidence interval.
aEstimated from weighted Poisson regression models. To calculate weight, probability of initiating cinacalcet was predicted by age, sex, vintage, primary renal disease, cardiovascular disease, lung disease, liver disease, malignancy, parathyroidectomy, time-varying value of VDRA, phosphate binder, serum Ca, serum inorganic Phosphorus, serum iPTH, dialysate Ca, Kt/V, serum Alb, BMI, Hgb, interaction terms of treatment variables and MBD variables, and visit number. To examine effect modification by baseline iPTH, baseline iPTH and its interaction with cinacalcet use were added to the weighted Poisson regression models.
bEstimated from case-cohort studies.
cEstimated from cohort study.